Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon A Rodan

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivativeMichael J Breslin, Mark E Duggan, Wasyl Halczenko, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacementsKaren M Brashear, Cecilia A Hunt, Brian T Kucer, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.
Molecular Endocrinology (Baltimore, Md.)|October 15, 2005
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylationLorraine Lipfert, John E Fisher, Nan Wei, et al.
The Journal of Biological Chemistry|October 23, 2009
Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glandsAzriel Schmidt, Shun-Ichi Harada, Donald B Kimmel, et al.
Journal of Medicinal Chemistry|September 17, 2004
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosisPaul J Coleman, Karen M Brashear, Ben C Askew, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Journal of Medicinal Chemistry|October 17, 2003
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosisJohn H Hutchinson, Wasyl Halczenko, Karen M Brashear, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2008
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin KJacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivativeMichael J Breslin, Mark E Duggan, Wasyl Halczenko, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacementsKaren M Brashear, Cecilia A Hunt, Brian T Kucer, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.
Molecular Endocrinology (Baltimore, Md.)|October 15, 2005
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylationLorraine Lipfert, John E Fisher, Nan Wei, et al.
The Journal of Biological Chemistry|October 23, 2009
Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glandsAzriel Schmidt, Shun-Ichi Harada, Donald B Kimmel, et al.
Journal of Medicinal Chemistry|September 17, 2004
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosisPaul J Coleman, Karen M Brashear, Ben C Askew, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Journal of Medicinal Chemistry|October 17, 2003
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosisJohn H Hutchinson, Wasyl Halczenko, Karen M Brashear, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2008
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin KJacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish, et al.
Pageof 5